AMSTERDAM, June 10, 2016 /PRNewswire/ -- Royal
Philips (NSYE: PHG, AEX: PHIA) today announced that it will be
showcasing solutions at the Society of Nuclear Medicine and
Molecular Imaging (SNMMI) 2016 Annual Meeting in San Diego, Calif., highlighting Philips'
legacy of innovation. Recognizing molecular imaging's unique
ability to transform healthcare, Philips has developed high-quality
imaging solutions that aim to increase diagnostic confidence,
enhance the patient experience and care, and lower costs –
expanding the advancements seen over the past 125 years as a
company.
"Our dedication to developing solutions for enhanced diagnosis
and treatment can be seen across Philips, demonstrated by our
continued commitment to deliver health technology to drive
better outcomes across the health continuum," said
Kirill Shalyaev, Ph.D., Vice President and General Manager,
Advanced Molecular Imaging, Philips. "Philips' proven
solutions and advanced innovations in molecular imaging are
enabling fast and confident decision making."
Nuclear medicine technology has significantly evolved over the
years – growing from scanner-only equipment to solutions that
integrate quality, quantification and analytics. Ten years ago,
also in San Diego, Philips
introduced the first commercial Time-of-Flight PET/CT. Over the
last decade, this technology has continued to improve and today,
time-of-flight is faster, better, and digital. This year,
over 20 oral and poster sessions featuring Philips' digital photon
counting PET system will be presented at the SNMMI meeting,
highlighting the technology's full range of capabilities and
Philips' work with academic partners.
"The Wright Center of Innovation team at The Ohio State University and Philips have been very
successful partners in the clinical evaluation of the next
generation digital PET/CT," said Michael V. Knopp, MD, PhD,
Professor of Radiology at The Ohio State
University Wexner Medical Center. "In this year's SNMMI
Annual Meeting, we will present over 20 scientific presentations
and posters on these efforts demonstrating performance and benefits
of PET digital photon counting in the areas of lesion
detectability, radiation dose management and quantitative
imaging."
As our population continues to age and exponentially grows in
the coming years, coinciding with the prevalence of multiple
chronic and complex diseases such as cancer, dementia and cardiac
diseases, health imaging will require a more integrated and
inter-disciplinary approach toward treatment. Given the unique
clinical insights it provides, molecular imaging will play even
more of a critical role in addressing complex diseases – as a
result, the advanced data and analytics found in these technologies
will be essential to improving patient care.
Philips' SNMMI exhibit (Booth 1330, Hall E) will feature the
latest solutions and technologies driving nuclear medicine, and
will highlight the following milestones:
- A decade of Time of Flight – Launched ten years ago,
Time-of-Flight technology continues to hold the promise of better
PET imaging. Since it was first brought to market in 2006, it has
grown to be an integral piece in Philips' portfolio of PET/CT
solutions. Today, time-of-flight is faster, better and digital in
products such as Vereos, the world's first fully digital PET/CT.
Time-of-Flight technology is now bridging innovation with digital
architecture available in Philips solutions – meaning high quality
images and enhanced lesion detectability.
- Advanced data sharing – Data sharing gives physicians
the power to visualize, diagnose and communicate across clinical
domains and imaging modalities with one automated workflow.
Philips' latest edition of its advanced data sharing, analytics and
visualization platform, Intellispace 8.0, helps physicians detect,
diagnose and follow up on treatment of diseases, offering a
comprehensive advanced visualization suite for multi-modality tumor
tracking, characterization and assessment.
- Flexibility of PET/CT – Philips PET/CT systems allow
physicians to go beyond current limitations in standard PET/CT
imaging, with capabilities such as digital imaging, and can now
meet a wide range of clinical and economic needs in CT lung cancer
screening.
For more information on Philips' molecular imaging solutions,
and to learn more about the company's presence at SNMMI 2016, visit
Booth 1330, Hall E; www.philips.com/snmmi and follow the
conversation on @PhilipsLiveFrom.
For further information, please contact:
Adrienne Smith
Philips Diagnostic Imaging
Tel: +1 781-277-1170
Email: Adrienne.Smith@philips.com
Kathy O'Reilly
Philips Group Communications
Tel: +1 978-221-8919
Email: Kathy.oreilly@philips.com
@kathyoreilly
About Royal Philips
Royal Philips (NYSE: PHG, AEX:
PHIA) is a leading health technology company focused on improving
people's health and enabling better outcomes across
the health continuum from healthy living and prevention, to
diagnosis, treatment and home care. Philips leverages advanced
technology and deep clinical and consumer insights to
deliver integrated solutions. The company is a leader in
diagnostic imaging, image-guided therapy, patient
monitoring and health informatics, as well as
in consumer health and home care.
Headquartered in the Netherlands,
Philips' health technology portfolio generated 2015 sales of
EUR 16.8 billion and employs
approximately 69,000 employees with sales and services in more than
100 countries. News about Philips can be found at
www.philips.com/newscenter.
Logo -
http://photos.prnewswire.com/prnh/20140122/NE50581LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/philips-reaffirms-commitment-to-advanced-molecular-imaging-at-snmmi-2016-annual-meeting-300283167.html
SOURCE Royal Philips